Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WRAPUP 5-Europe enacts new curbs as COVID surges in absence of vaccine

Tue, 27th Oct 2020 10:57

(Adds Spain, EU)

* Anti-restriction protests turn violent in Italy

* France warns of "difficult decisions" ahead

* Trump pushes vaccines, but none yet available

By Crispian Balmer

ROME, Oct 27 (Reuters) - European governments moved on
Tuesday to impose new curbs to try to rein in a fast-growing
surge of coronavirus infections and provide economic balm to
help businesses survive the pandemic.

World leaders face an increasingly difficult task holding
the disease at bay while keeping their economies afloat as they
pin their hopes on as-yet unproven vaccines.

"We are dealing with exponential growth," German Economy
Minister Peter Altmaier told a virtual German-French economic
conference in Berlin. "In Germany the number of new infections
is rising by 70-75% compared to the week before."

The United States, Russia, France, Sweden, Poland and other
countries have registered record numbers of infections in recent
days as autumn turns to winter in the Northern Hemisphere and
people socialise indoors where the risk of infection is higher.

More than 43.4 million people have been infected by the
coronavirus globally and 1,158,056? have died, according to a
Reuters tally, with the United States leading the way in the
number of infections and deaths.

Hundreds of protesters took to the streets across Italy on
Monday to vent their anger at the latest round of restrictions,
including early closing for bars and restaurants, with
demonstrations in some cities turning violent.

In the financial capital Milan, youths hurled petrol bombs
at police, who responded with volleys of tear gas. In nearby
Turin, luxury shops had their windows smashed and some were
ransacked, leading to the arrest of 10 rioters.

In France, Interior Minister Gerald Darmanin warned the
country to prepare for "difficult decisions" after some of the
strictest restrictions currently in place anywhere in Europe
have failed to halt the spread of the disease.

The Czech government will ask lawmakers to extend its
emergency powers until Dec. 3, Prime Minister Andrej Babis said
on Tuesday, as it tries to stem one of the strongest surges in
infections in Europe.

BRAIN FUNCTION AFFECTED

There have been at least 8.54 million reported infections
and 251,000 deaths caused by coronavirus in Europe so far,
according to latest Reuters data. The continent registered a
record 230,892 new cases on Monday, up from 67,739 on Oct. 1.

Authorities in Russia, which with 1.55 million infections
has the world's fourth largest COVID-19 case load, ordered
people to wear facemasks in some public places and asked
regional authorities to consider shutting bars and restaurants
overnight.

New infections in Belgium, among the hardest-hit countries
in Europe, hit a high of more than 18,000 on Oct. 20, almost a
10-fold increase from the high of a spring wave of the pandemic.

The country is expected to decide by this weekend whether a
return to a nationwide lockdown is required.

Even Germany, widely praised for its initial response to the
pandemic, signalled concern on Tuesday over rising infections,
with Altmaier saying the country was likely to reach 20,000
cases a day by the end of this week.

Spain's wine-producing region of La Rioja ordered the
closure of restaurants and bars in its two largest towns for a
month. A nationwide curfew has been in place since Sunday.

A gauge of global stock markets fell and the U.S. dollar
slipped on Tuesday as investors grappled with a surge in
coronavirus cases and uncertainty over the impending U.S.
election.

Adding to the gloomy sentiment, a new study by Imperial
College London found that antibodies against the new coronavirus
declined rapidly in the British population during summer,
suggesting protection after infection may not be long-lasting.
Recovering patients may also suffer a decline in
brain function, researchers warned.

In the United States, the number of hospitalised COVID-19
patients is at a two-month high, straining health care systems
in some states. The U.S. death toll leads the world at more than
225,300.

"Until November 4th., Fake News Media is going full on
Covid, Covid, Covid," President Donald Trump, facing a tough
re-election battle on Nov. 3, tweeted on Tuesday in an
often-repeated refrain without offering evidence. "We are
rounding the turn. 99.9%."

Trump has often promoted vaccines as the answer, but none
has yet won international approval. Russia in August became the
first country to grant regulatory approval for a vaccine after
less than two months of human testing, raising eyebrows among
sceptical scientists in the West.

A vaccine being developed by the University of Oxford and
AstraZeneca Plc produces an immune response in both old
and young adults, the company said on Monday, raising hopes of a
path out of the gloom.

But only a share of the EU population can be inoculated
before 2022, should a vaccine become available, EU officials
said in an internal meeting on Tuesday.

The warning comes in spite of the fact that the 27-nation
bloc, with a population of 450 million, has secured more than a
billion doses of potential vaccines from three drugmakers.

(Reporting by Reuters bureaux; Writing by Crispian Balmer and
Nick Macfie; Editing by Alison Williams and Jon Boyle)

More News
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.